Navigation Links
CuraGen Corporation Receives Notification from NASDAQ
Date:1/29/2008

r technical, scientific, regulatory or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in CuraGen's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, CuraGen's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CRGN-F

Contacts:

Glenn Schulman, PharmD

Director of Investor Relations

gschulman@curagen.com

(888) 436-6642


'/>"/>
SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
2. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
3. CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference
4. CuraGen Appoints Clinical Oncologist as VP of Medical Development
5. CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
6. Healionics Corporation Completes Series A Financing
7. Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008
8. China Bionanometer Industries Corporation Announces Record Second Quarter 2007 Results
9. Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation
10. Sigma-Aldrich Corporations 4th Quarter 2007 Earnings Conference Call
11. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Albany, New York (PRWEB) August 22, 2014 ... represent one of the interesting and challenging endeavors ... eye renders highly impervious properties to the foreign ... such as possibility of self medication and minimal ... of low molecular weight drugs and provides specific ...
(Date:8/22/2014)... The Global and China Diabetes Drugs Industry is ... of the Diabetes Drug industry in Global and China. ... industry, including definitions, applications and industry chain structure. Global ... with a focus on history, developments, trends and competitive ... and Chinese situation is also offered. , The report ...
(Date:8/22/2014)... -- Research and Markets has announced the ... Chromatography (GPC) Industry Report 2014" report to their ... Permeation Chromatography (GPC) Industry Report is a professional and ... gel permeation chromatography industry with a focus on the ... of the industry including definitions, classifications, applications and industry ...
(Date:8/22/2014)... Aug. 22, 2014 Research and Markets ... Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, ... report to their offering. The global ... in 2013, and is expected to grow at a ... Molecular biology enzymes, kits, & reagents find applications in ...
Breaking Biology Technology:Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Diabetes Drugs Industry Growth Analysis in Global, China Regions Research Report Available at DeepResearchReports.com 2Diabetes Drugs Industry Growth Analysis in Global, China Regions Research Report Available at DeepResearchReports.com 3Global and China Gel Permeation Chromatography (GPC) Industry Report 2014 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 3
... , , , ... of hospital-related infections in the U.S. costs up to $11 billion a ... implanted in patients. Until now, efforts to control drug-resistant biofilms on such ... mats developed by collaborators Pat Mather and Dacheng Ren of the Syracuse ...
... ... announced the PX14400 high-speed digitizer, the industry,s most advanced wideband and high dynamic ... when using the programmable gain amplifier in 1 dB steps for maximum gain ... is employed for the cleanest possible signal path to the ADC. 1 GB ...
... /PRNewswire/ - Enerkem, a leading waste-to-biofuels and green chemicals ... by its partners, the City of Edmonton and the ... on their joint advanced energy research facility. The ceremony ... Advanced Education and Technology in Alberta, and the Edmonton ...
Cached Biology Technology:New Antimicrobial Webs Sterilize Medical Implants for 14 Days 2Signatec Unveils PX14400, Its High-Speed PCI-Express Digitizer Capable of Sustained Recordings Over 1.2 GB/s with Xilinx Virtex-5 FPGAs for Embedded Real-Time Processing 2Signatec Unveils PX14400, Its High-Speed PCI-Express Digitizer Capable of Sustained Recordings Over 1.2 GB/s with Xilinx Virtex-5 FPGAs for Embedded Real-Time Processing 3Signatec Unveils PX14400, Its High-Speed PCI-Express Digitizer Capable of Sustained Recordings Over 1.2 GB/s with Xilinx Virtex-5 FPGAs for Embedded Real-Time Processing 4Enerkem Announces Construction Start on Advanced Energy Research Facility in Edmonton, Alberta 2Enerkem Announces Construction Start on Advanced Energy Research Facility in Edmonton, Alberta 3
(Date:8/21/2014)... by an international standards process, will be available soon ... invited review published in the OnlineFirst version of ... official journal of the American Society for Parenteral and ... the occurrence of misconnection that can be harmful and ... used to join medical devices, components, and accessories to ...
(Date:8/21/2014)... has successfully replicated one of the crucial steps in ... sunlight which could manufacture hydrogen as a fuel. , ... an exciting prospect to use them to create hydrogen, ... Hingorani, from the ARC Centre of Excellence for Translational ... Hydrogen offers potential as a zero-carbon replacement for petroleum ...
(Date:8/21/2014)... in severe abdominal pain, vomiting and systemic inflammation. Every ... with the disease resulting in 1000 deaths. There is ... fluid and nutritional support. , Dr Jason Bruce, ... research, said "The major causes of pancreatitis include bile ... combined with a high fat diet. In fact, the ...
Breaking Biology News(10 mins):New feeding tube connectors will improve patient safety 2Water and sunlight the formula for sustainable fuel 2Insulin offers new hope for the treatment of acute pancreatitis 2
... and the Fudan University in Shanghai, China, have found ... forests -- may lower the potential of forests for ... ecology in the OU College of Arts and Sciences ... Li and Changming Fang, professors of ecology in the ...
... This release is available in German . ... approved the establishment of twelve new Collaborative Research Centres (CRC) ... Grants Committee at its spring meeting in Bonn. The new ... total of 112 million euros (including a 20% programme allowance ...
... Scientists using tiny particles of genetic material to interfere ... have successfully prevented monkeys exposed to that virus from ... this week,s issue of The Lancet , suggests ... "Over the past decade, we have evaluated numerous ...
Cached Biology News:Study finds reforestation may lower the climate change mitigation potential of forests 2DFG approves 12 new collaborative research centers 2DFG approves 12 new collaborative research centers 3DFG approves 12 new collaborative research centers 4DFG approves 12 new collaborative research centers 5DFG approves 12 new collaborative research centers 6Experimental treatment protects monkeys from lethal Ebola virus post-exposure 2Experimental treatment protects monkeys from lethal Ebola virus post-exposure 3
Yellow oily liquid. Contains 85% Drakeol 5NF, 15% Arlacel A (mannide monooleate emulsifier). Heat sterilized. Contains zero colony forming units/ml. ...
... 470 nm; includes interface cable to S2000; can ... rack or desktop boxes The LS-450 ... that produces either pulsed or continuous output at ... fluorescence measurements. The source is designed for use ...
... miRCURY Array LNA microarray slides for ... microarray slides incorporate Exiqons unique Locked Nucleic ... and excellent mismatch discrimination for short microRNA ... less than 1 g total RNA (no ...
... slightly cloudy liquid. Yellow, oily, bacterial ... each containing 10 ml of Freund's ... proportions by weight: 85% Drakeol 5NF, ... and 0.1% Mycobacterium butyricum ...
Biology Products: